Frontiers 22 Bergamo Session 8: When and How to Inhibit C3 in Complement-mediated Rare Nephropathies
Recorded On: 07/11/2022
- Registration Closed
Already registered?
Log in now.
- Manipulating the Early Steps of Complement Cascade: Emerging Drugs, Potential Risks, and Benefits
- Lessons from Studies in Mouse Models of C3G
- Targeting C3, CFD, or CFB in C3G, Preliminary Results of Clinical Trials in Patients with C3G/IC-MPGN
- Oral Presentation from Abstract Selection
- Q&A Discussion
Joshua Thurman
USA
Ariela Benigni
Italy
Complete
Next
Failed
Available
Locked